A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 521 participants.

Also called NCT04109547

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 521 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04109547
  • EudraCT 2018-002590-22
Other papers using this trial's data
  • Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial Diabetologia, 2024-09 DOI, PubMed 38985162, PMC11410837 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Algeria, China, Hungary, Serbia, Taiwan, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04109547. Randomized; quadruple masking; primary purpose treatment. Start 2019-10-01 (actual); primary completion 2021-09-23 (actual). Results posted on 2023-09-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
Acronym
PIONEER 11
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Oral semaglutide
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04109547
Content hash
27b722b3ffd3f82434312370808209c79ed1539ce41780342f5dd660358fbe09